◆ 会议时间：2026年6月25-27日
◆ 会议地点：新加坡（Singapore）

◆ 会议简介：

2026年美国临床肿瘤学会突破峰会(ASCO Breakthrough)将于2026年6月25-27日在日本横滨举行。ASCO Breakthrough是由美国临床肿瘤学会(ASCO)在亚洲召开的创新型会议。ASCO Breakthrough将肿瘤学领域的领导者、执业临床医生、医疗技术带头者、新药开发人员和研究开拓者聚集在亚洲这一不容错过的肿瘤学会议上以寻求灵感、协作和解决方案。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）.

ASCO Breakthrough 2026

Date:
June 25-27, 2026

Venue:
Raffles City Convention Centre | Singapore & Online

Co-Hosted by：
American Society of Clinical Oncology (ASCO)

Transforming Cancer Care Through Innovation & Discovery
As innovations in cancer care technology accelerate progress and improve patient outcomes, ASCO Breakthrough brings together oncology thought leaders, practicing clinicians, med-tech pioneers, novel drug developers, and research trailblazers at this can’t-miss oncology meeting in Asia for inspiration, collaboration, and solutions.

摘要征文投稿：

Abstract Submission Opens: December 3, 2025
Abstract Submission Deadline: February 24, 2026, at 11:59 PM (ET)
Abstract Change/Withdrawal Deadline: May 12, 2026, at 12:00 PM (ET)

点此提交摘要>>>Submit Abstract>>>

点此查看更多摘要提交相关信息>>>

Submission Requirements

• ASCO Account: To submit an abstract, you will need to log in with an ASCO.org.org account. If you are not an ASCO member, you can create a guest account. The person submitting the abstract is not required to be an author on the abstract and will be able to select the first/presenting author on the designated step. However, the first author will need to accept/agree to all ASCO policies and will be held responsible for any violation of the policies.
• Identification of Original Research: Indicate whether your abstract reports on original research. Original research means a systematic investigation designed for the purpose of expanding knowledge or understanding, including the analysis of data.
• Identification of Clinical Trials: Indicate whether your research is a clinical trial. A clinical trial is: a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes (National Institutes of Health [NIH] Office of Extramural Research.)
  • Though clinical trial registration is not required for abstract submission, publication, or presentation, certain clinical trials are required to be registered by law and/or prior to journal publication. If a clinical trial is already registered, the first author will be asked to provide the name of the registry and the trial registration number during the abstract submission process. The clinical trial number will be included as part of the published abstract. 
• Funding Source: Indicate whether the abstract was funded by the NIH, a pharmaceutical or biotechnology company, a tobacco company, a foundation, or another source
• Abstract Title: The title should objectively describe the study. Do not refer to study results or conclusions. ASCO reserves the right to edit conclusive titles.
• Coauthor(s): Provide the full name, academic degree(s), institution, address, email address, and disclosure information for each author. You may list up to 20 individual authors for each abstract.
• Disclosure Declaration: ASCO’s policy promotes balance, independence, objectivity, and scientific rigor in all of its activities through the disclosure of financial interests and other relationships, and the management of potential conflicts. The financial interests or relationships requiring disclosure are outlined in ASCO’s Policy For Relationships With Companies (Journal of Clinical Oncology 2017 35:7, 796-798). All authors are expected to disclose all relationships with for-profit health care companies.
  • Author disclosure must be declared at the time of abstract submission. If the first author is employed by a company or holds ownership with a private company (see company definition below), an alternate presenter who does not have a relevant employment or ownership relationship must be named from the list of coauthors if the abstract is selected for presentation in an education session, oral abstract session, or rapid oral abstract session.
    • Company: an entity whose business is developing, producing, marketing, selling, re-selling or distributing drugs, devices, services or therapies used to diagnose, treat, monitor, manage and alleviate health conditions
  • The Coauthor Disclosure Form may be used by the first author to obtain disclosure information from coauthors. The first author must enter all disclosure information through the Abstract Submitter.
  • If an author has provided disclosure through the ASCO Disclosure Management System, the information will automatically populate in the submission site. Disclosure information for all authors will be distributed as part of abstract presentation materials.
• Abstract Body/Table: The body of your abstract should describe the background, methods, results, and conclusions of your research. You may type your abstract directly into the text box, cut and paste it from an existing document, or upload a text file of your abstract. Do not exceed 2,600 characters (approximately 300 to 350 words) for the total of your abstract title, body including section titles, and table. The character count does not include spaces or author names or institutions. One data table is permitted per abstract. The composition process does not enable shading or the merging of cells with centered text. Limit your table to no more than 10 rows and eliminate the need for shading or merged cells with centered text. Illustrations and figures are not permitted.
• Submission Track: Select the most appropriate track and subcategory for the abstract (see Submission Tracks and Subcategories). The ASCO Breakthrough Meeting Program Committee has the authority to recategorize an abstract.
• Submission Fee: A $40 (USD) non-refundable submission fee will be charged per abstract submitted. Payment is due at the time of submission.

◆ 参会对象：
肿瘤科医师、放射科医师，介入放射科医师，外科/普外科医师，病理科医师，护士以及从事肿瘤护理与研究的其他相关专业人士等。